MDM2 and melanoma: Furthermore, combination treatment with GSK280371 and an MDM2 inhibitor has been shown to result in increased growth inhibition and cytotoxicity in a wide range of cancer cell types, including melanoma, osteosarcoma, colon carcinoma, neuroblastoma, and breast and ovarian cancer cells [21,23,30].